CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2017—Trovagene has entered into a long-term supply and distribution agreement with Boreal Genomics in which they will merge their respective technologies to co-develop urine and blood ctDNA assay kits. The companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine, and low-cost urine and blood ctDNA assay for next-generation sequencing platforms run by laboratories of research institutions, cancer centers, and service facilities around the world.
Read More »